Udihep Forte 300mg Tablets 50’s

Udihep Forte 300mg Tablets 50’s is a biliary agent, prescribed for gallstones. It helps to dissolve the stone by reducing the amount of cholesterol released by liver into bile. Therapeutic indications: Udihep tablets are indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder. Cholesterol stones coated with calcium or stones composed of bile pigments are not dissolved by ursodeoxycholic acid. Urdox has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.

How to use

Posology and method of administration: Udihep tablets are for oral administration, to be taken with a drink of water.
Primary Biliary Cirrhosis: Adults and Elderly: 10 – 15mg ursodeoxycholic acid (UDCA) per kg per day in two to four divided doses.
Children: Dosage should be related to bodyweight. Dissolution of gallstones: Adults and Elderly: The usual dose is 6 – 12mg/kg/day either as a single night time dose or in divided doses. This may be increased to 15mg/kg/day in obese patients, if necessary. The duration of treatment may be up to two years, depending on the size of the stone(s), and should be continued for three months after the apparent dissolution of the stone(s).
Children: Dosage should be related to bodyweight.
Paediatric population: Children with cystic fibrosis aged 6 year to less than 18 years: 20 mg/kg/day in 2-3 divided doses, with further increase to 30 mg/kg/day if necessary.

Precautions

Contraindications: Ursodeoxycholic acid should not be used in patients;
1. with radio-opaque calcified gall-stones.
2. with acute inflammation of the gall bladder or biliary tract.
3. with occlusion of the biliary tract (occlusion of the common bile duct or a cystic duct)
4. with frequent episodes of biliary colic
5. with impaired contractability of the gall bladder
6. with hypersensitivity to bile acids or any excipient of the formulation
7. who are pregnant or breastfeeding, or in women who may become pregnant.
8. with chronic liver disease, peptic ulcers or in those with inflammatory diseases of the small intestine and colon.
Paediatric population: Unsuccessful portoenterostomy or without recovery of good bile flow in children with biliary atresia